Neutralization of complement inhibitors as a concept to increase the efficacy of therapeutic antibodies was exploited by testing bi-specific antibodies targeting CD20 and CD55 either in vitro or in a murine xenograft model of Burkitt lymphoma [29]. Here, MS4A1 is linked to Burkitt lymphoma.